B+
Bull case
15%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
LPCN
LipocineCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The new placebo-controlled PPD study and scheduled Q3 FDA guidance meeting could preserve a development path for LPCN 1154, while the UAE authorization and additional TLANDO partnerships provide commercial optionality [#SEC-8K-2026-08-04].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional development, partnership, or financing decisions could create execution and dilution risk.
Momentum
100
Value
58
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $4.50 · Bear $1.20Analysis 2026-08-06; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum100 · Δ7d -
Value58 · Δ7d -0.0
Sentiment56 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Additional development, partnership, or financing decisions could create execution and dilution risk.
- • FDA guidance may not support a viable validation-study or approval pathway.
- • The pivotal LPCN 1154 trial missed its primary endpoint, and the proposed rescue path depends on post hoc analyses, regulatory feedback, and another trial.
Catalyst clock
2026-08-15
Q2 earnings digestion highlights limited commercial base
Lead driver: Sentiment · See AI snapshot
Momentum
100
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.7
Sentiment
56
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 99.5 / Value 58.0 / Sentiment 56.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-06. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
B-
Bear case
40%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-08-06 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$16.9M
Beta
0.99
Shares Out
8.24M
P/E (TTM) · Derived
-1.2
P/S (TTM)
9.38
P/FCF (TTM) · Derived
-1.16
Rev YoY
-69.5%
EPS YoY
-22.5%
Gross Margin
+96.3%
Op Margin
-800.8%
Net Debt
-$14.93M
Current Ratio
11.48
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data